{"title":"PP01.65:一项单一机构研究:阿法替尼作为LMIC环境中奥西替尼更便宜的替代方案,在具有外显子19缺失和外显子21 L858R突变的晚期NSCLC一线治疗的实际经验","authors":"Dr. Anupam Datta , Dr. Soumita Majumder","doi":"10.1016/j.jtho.2026.103808","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"21 5","pages":"Article 103808"},"PeriodicalIF":20.8000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PP01.65: Real-World Experience of Afatinib as First Line Treatment in Advanced NSCLC with Exon 19 Deletion and Exon 21 L858R Mutations as a Cheaper Alternative to Osimertinib in an LMIC Setting: A Single Institutional Study\",\"authors\":\"Dr. Anupam Datta , Dr. Soumita Majumder\",\"doi\":\"10.1016/j.jtho.2026.103808\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":\"21 5\",\"pages\":\"Article 103808\"},\"PeriodicalIF\":20.8000,\"publicationDate\":\"2026-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1556086426002613\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/5/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086426002613","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
PP01.65: Real-World Experience of Afatinib as First Line Treatment in Advanced NSCLC with Exon 19 Deletion and Exon 21 L858R Mutations as a Cheaper Alternative to Osimertinib in an LMIC Setting: A Single Institutional Study
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.